Plain-English translation of NCT05323201 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment called fhB7H3.CAR-T cells—your own immune cells that have been genetically engineered in a lab to recognize and attack liver cancer cells. Researchers believe this medication could help people with advanced liver cancer that cannot be removed by surgery. The study will test whether the treatment is safe and whether it works to slow or shrink the cancer.
Advanced liver cancer is difficult to treat with standard therapies, and many patients have limited options. Researchers have discovered that a specific marker called B7H3 appears on liver cancer cells, which makes it a promising target. This trial is testing whether this new medication can be an effective treatment option for patients who need it most.
You likely qualify if…
You likely don't qualify if…
If you qualify, your own immune cells will be collected from your blood and sent to a lab where they are genetically modified over several weeks. You will receive chemotherapy for three days to prepare your body, then the engineered cells will be infused back into you through a catheter placed in a blood vessel near your liver. After infusion, you will have frequent blood draws and monitoring appointments—twice a week for the first month, then monthly for three months, then every three months for two years, and finally yearly for up to five years total.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China